<SEC-DOCUMENT>0001654954-22-005667.txt : 20220429
<SEC-HEADER>0001654954-22-005667.hdr.sgml : 20220429
<ACCEPTANCE-DATETIME>20220429160940
ACCESSION NUMBER:		0001654954-22-005667
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220429
DATE AS OF CHANGE:		20220429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		22875372

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>cvm_defa14a.htm
<DESCRIPTION>DEFA-14A
<TEXT>
<html><head><title>cvm_defa14a.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: left; FONT: 10pt Times New Roman"><table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:12pt">UNITED STATES</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:12pt">SECURITIES AND EXCHANGE COMMISSION</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:12pt">WASHINGTON, D.C. 20549</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">SCHEDULE 14A INFORMATION</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Filed by the Registrant&nbsp; &nbsp;&nbsp; &#9746;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Filed by a Party other than the Registrant&nbsp;&nbsp;&nbsp; &nbsp;&#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Check the appropriate box:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#9744;&nbsp; &nbsp;&nbsp; Preliminary Proxy Statement&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#9744;&nbsp; &nbsp;&nbsp; Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2))&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#9744;&nbsp;&nbsp;&nbsp; &nbsp;Definitive Proxy Statement&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#9746;&nbsp;&nbsp;&nbsp; &nbsp;Definitive Additional Materials&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting Material under Rule 14a-12&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;&nbsp; </p> <table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">CEL-SCI CORPORATION</font></strong></p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>(Name of Registrant as Specified In Its Charter)</em></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">_________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Payment of Filing Fee (Check the appropriate box):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#9746;&nbsp; &nbsp;&nbsp; No fee required&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#9744;&nbsp; &nbsp; &nbsp;Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title of each class of securities to which transaction applies:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Aggregate number of securities to which transaction applies:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(3)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(4)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Proposed maximum aggregate value of transaction:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(5)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Total fee paid:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp; Fee paid previously with preliminary materials.&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;&nbsp;&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp; Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;&nbsp;&nbsp;&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Amount Previously Paid:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Form, Schedule or Registration Statement No.:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(3)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Filing Party:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(4)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Date Filed:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;&nbsp; </p> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>8229 Boone Blvd., Suite 802</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Vienna, Virginia 22l82</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(703) 506-9460</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_defa14aimg1.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">April 2022</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Dear Fellow Shareholders:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Thirty-five years ago I joined CEL-SCI as its second employee. The idea was to help cancer patients by activating the immune system to fight cancer. I had no idea how long and how difficult this journey would be. Throughout those years I was joined by the most amazing group of people: smart, kind, loyal and incredibly persistent. Most of our senior team has been together for almost 30 years. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">In early-2011, we started the Phase 3 study for our Multikine* in advanced primary head and neck cancer. No new therapies for this disease had been approved by the FDA in many decades. We were determined to show that adding our Multikine immunotherapy to the standard treatments of surgery, radiation and sometimes also chemotherapy could help patients live longer and better lives. Little did we know how long and hard that path would be&#8212;but we have now completed the Phase 3 study.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">In June 2021 we announced that we saw a huge survival benefit in our Phase 3 study for Multikine patients who received surgery and radiation after our Multikine treatment. Since that time we have received many calls asking us for additional trial data explaining how our Multikine could help these head and neck cancer patients live so much longer when other studies by big pharmaceutical companies have failed to show any survival benefit. We filed that very important additional clinical trial data with <u>www.clinicaltrials.gov</u>, the U.S. Government website for clinical trials, on March 22, 2022 and hoped that it would be public by now so that we could add the results to this letter. The information, however, is not yet public and could therefore not be included in this letter, but we hope that you will have seen the data by the time you receive this letter. Yet additional data will be presented and published in peer reviewed scientific forums in the future. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><em>&nbsp;</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The biotech stock market has been undergoing the worst sell-off in my 35 years in this business. That does not make things easier for us nor does it make us happy. However, we have been through many brutal downturns in the biotechnology markets and have always recovered. I believe that we are well positioned to recover from this storm as well since 1) we have cash until about the end of 2023 and 2) we have a finished 10-year clinical trial that has shown large survival benefit in a large cancer population that represents an unmet medical need. We have hired leading experts in the field to help get Multikine approved for sale. We are also working on scientific publications and the validation of our full scale manufacturing facility dedicated to making Multikine. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">This is not a process where we can easily give simple and regular updates, as we must respect the integrity and confidentiality of the regulatory review process. Please keep in mind that we have dedicated our lives to this important project and we will do everything possible to make this happen. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Thank you for your support.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Sincerely,</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Geert Kersten</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Chief Executive Officer</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><em>* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company&#8217;s future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>cvm_defa14aimg1.jpg
<TEXT>
begin 644 cvm_defa14aimg1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !K . # 2(  A$! Q$!_\0
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M6K1G2J>S>YZ&%QM/$T56B[1\]+6[E[#>M.Y]:P/^$P\+?]!RR_[_ "_XT?\
M"8>%O^@Y9?\ ?Y?\:GV53^5_<:_7</\ \_(_>;S4PG-87_"7^%_^@[9?]_EK
M3L[ZRO[5;JSF2>%LE9$;*G''6I=.4=9)HTIXBC4=H33?DTRT-P/.*DXQ6+9^
M(M%U"[^RV>I6\]Q@GRTD!; Z\5L]JF2E%VDK&D*D:BYH-->1R_C#Q,OAC0VU
M#RO.E9Q%%'G 9CZGT&#7$>&?B=?ZAK]OIVK6MN(KEQ&DD *E6/3().1VKO\
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MRXEE6!WEO(XHUE9I'!.[:W#88G\\]J&T&6XT+1-/FM[B6&*^\Z:.9E#+'B3
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MD,>F?>I_#%C<Z?J<D,>G216@C*M+<PHDJL&X7>I_>CJ=Q&?<YKM:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
